KEYNOTE-024 shows first-line pembrolizumab has long-term overall survival benefit in patients with advanced non-small cell lung cancer and PD-L1–expressing disease.
Although historically, the 5-year OS rate for patients with advanced NSCLC treated with chemotherapy is less than 5%, patients treated with nivolumab had a 5-year OS of 13.4%.
Preclinical studies performed in cell line and mouse models of lung adenocarcinoma showed that mesothelin-directed CAR-T was effective and not associated with toxicity.
OS was significantly higher in the subgroup of patients with high tumor expression of PD-L1 who received atezolizumab plus chemotherapy compared with chemotherapy alone.
Disease progression was accelerated in nearly 21% of NSCLC patients who received immunotherapy during the trial, suggesting this treatment may be detrimental for some.
The incidences of grade 3/4 AEs were high but similar in both study arms, although the rate of hematologic AEs was higher in the chemotherapy alone arm.
QoL measures either remained unpublished — despite being studied — or were not reported at all.
Continued molecular stratification in lung cancer appears imminent, and many of the patients in these genetic subgroups may benefit from the use of targeted therapies.
Fewer than 2% of the people in the LIBRETTO-001 study discontinued treatment with selpercatinib due to treatment-related adverse events.
Of the 23 patients with NSCLC who were evaluable for efficacy, the overall response rate was 48%, with a disease control rate of 96%.
Prophylactic cranial irradiation was determined to be tolerable; few adverse effects were observed in patients with stage III NSCLC receiving this treatment.
In this study, LKB1 mutations without coexisting KRAS mutations were found in the tumor specimens of 13.6% of patients with metastatic NSCLC.